PT3648788T - Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante - Google Patents

Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante

Info

Publication number
PT3648788T
PT3648788T PT187464581T PT18746458T PT3648788T PT 3648788 T PT3648788 T PT 3648788T PT 187464581 T PT187464581 T PT 187464581T PT 18746458 T PT18746458 T PT 18746458T PT 3648788 T PT3648788 T PT 3648788T
Authority
PT
Portugal
Prior art keywords
patients
administration
treatment
von willebrand
gastrointestinal bleeding
Prior art date
Application number
PT187464581T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3648788T publication Critical patent/PT3648788T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT187464581T 2017-07-07 2018-07-09 Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante PT3648788T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07

Publications (1)

Publication Number Publication Date
PT3648788T true PT3648788T (pt) 2024-08-23

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187464581T PT3648788T (pt) 2017-07-07 2018-07-09 Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante

Country Status (16)

Country Link
US (5) US10632176B2 (OSRAM)
EP (2) EP4424366A3 (OSRAM)
JP (2) JP7307047B2 (OSRAM)
KR (2) KR102921337B1 (OSRAM)
CN (1) CN111436193A (OSRAM)
AU (2) AU2018298233B2 (OSRAM)
BR (1) BR112020000321A2 (OSRAM)
CA (1) CA3069295A1 (OSRAM)
CO (1) CO2020001322A2 (OSRAM)
DK (1) DK3648788T3 (OSRAM)
ES (1) ES2986574T3 (OSRAM)
FI (1) FI3648788T5 (OSRAM)
MX (1) MX2025012580A (OSRAM)
PL (1) PL3648788T3 (OSRAM)
PT (1) PT3648788T (OSRAM)
WO (1) WO2019010497A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
AU2008261261B2 (en) 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
WO2009086400A2 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
WO2011017414A2 (en) 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
PT3626736T (pt) 2010-07-08 2025-08-11 Takeda Pharmaceuticals Co Método de produção de fvw recombinante de elevado peso molecular na cultura celular
KR101969515B1 (ko) 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf

Also Published As

Publication number Publication date
EP4424366A3 (en) 2024-12-04
KR102921337B1 (ko) 2026-02-02
CN111436193A (zh) 2020-07-21
AU2018298233A1 (en) 2020-01-30
RU2020105682A (ru) 2021-08-10
US20230122958A1 (en) 2023-04-20
ES2986574T3 (es) 2024-11-12
US10905746B2 (en) 2021-02-02
JP7641327B2 (ja) 2025-03-06
FI3648788T5 (fi) 2024-09-09
JP2023123738A (ja) 2023-09-05
KR20200037235A (ko) 2020-04-08
FI3648788T3 (fi) 2024-08-16
PL3648788T3 (pl) 2024-10-07
WO2019010497A1 (en) 2019-01-10
US11529395B2 (en) 2022-12-20
US20210169989A1 (en) 2021-06-10
EP3648788B1 (en) 2024-05-22
US20200206318A1 (en) 2020-07-02
US20240316160A1 (en) 2024-09-26
MX2025012580A (es) 2026-01-07
AU2018298233B2 (en) 2025-04-24
BR112020000321A2 (pt) 2020-07-14
DK3648788T3 (da) 2024-08-19
JP7307047B2 (ja) 2023-07-11
EP4424366A2 (en) 2024-09-04
AU2025205392A1 (en) 2025-09-25
CO2020001322A2 (es) 2020-02-18
JP2020526525A (ja) 2020-08-31
RU2020105682A3 (OSRAM) 2021-10-15
US12016904B2 (en) 2024-06-25
US10632176B2 (en) 2020-04-28
KR20260037107A (ko) 2026-03-17
EP3648788A1 (en) 2020-05-13
US20190091299A1 (en) 2019-03-28
CA3069295A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
PL3648788T3 (pl) Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf
MX2015015249A (es) Peptidos terapeuticos.
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
EP3071280A4 (en) TREATMENT CATHETER WITH THERAPEUTIC ENERGY SUPPLY
CL2015002456A1 (es) Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano
PL3624831T3 (pl) Rekombinowana ludzka alfa-glukozydaza kwasowa
EP3318879A4 (en) Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
MA50358A (fr) Sémaglutide en thérapie médicale
EP3643784A4 (en) RECOMBINANT HUMAN BASIC FIBROBLASTIC GROWTH FACTOR (RH-BFGF) AND PHARMACEUTICAL COMPOSITION INCLUDING RH-BFGF
SG10201912768YA (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
SG11201610947UA (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
SG11201608132UA (en) Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
EA201890163A1 (ru) Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью
PT3648787T (pt) Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
CO7131377A2 (es) Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos
PE20160877A1 (es) Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
AR104194A1 (es) Composición del factor de von willebrand
EP3492487A4 (en) PEPTIDE WITH TITANIUM BINDING ABILITY
EP3331559A4 (en) IMMUNE-LEADING RECOMBINANT DENGUE PROTEIN
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων
EP3823591A4 (en) MICRONIZED HUMAN INJECTABLE INSULIN
IT201700009222A1 (it) Composizione per la preparazione del paziente per la colonscopia virtuale